Final Terms Confirmation Announcement Europæiske

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Final Terms Confirmation Announcement Europæiske Medicinalvirksomheder 2019 (ISIN DK0030350426)

Copenhagen, 2014-12-17 10:28 CET (GLOBE NEWSWIRE) --

IMPORTANT NOTICE

In accessing the following notice you agree to be bound by the following terms and conditions.

The information contained in this notice may be addressed to and/or targeted at persons who are residents of particular countries only, as specified in the Final Terms and/or in the Base Prospectus (as defined below), and is not intended for use and should not be relied upon by any person outside those countries and/or to whom the offer contained in the Final Terms is not addressed. Prior to relying on the information contained in the Final Terms, you must ascertain from the Final Terms and/or the Base Prospectus whether or not you are an intended addressee of the information contained therein.

Neither the Final Terms nor the Base Prospectus constitutes an offer to sell or the solicitation of an offer to buy securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities law of any such jurisdiction.

The securities described in the Final Terms and the Base Prospectus have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the " Securities Act ") and may not be offered or sold directly or indirectly within the United States or to, or for the account or benefit of, U.S. persons or to persons within the United States of America (as such terms are defined in Regulation S under the Securities Act (" Regulation S ")). The securities described in the Final Terms will only be offered in offshore transactions to non-U.S. persons in reliance upon Regulation S.

Nordea Bank Finland Plc (the "Issuer")

Issue of DKK denominated Equity-Linked Notes due 19 December 2019

(Series A769, ISIN DK0030350426)

(the "Notes")

under the EUR10,000,000,000

Structured Note Programme


Final Terms Confirmation Announcement relating to the Final Terms dated 8 December 2014
 

Terms used herein shall be deemed to be defined as such for the purposes of the Final Terms dated 8 December 2014 (the " Final Terms ") relating to the offer of the Notes, the base prospectus dated 20 December 2013 and the supplements to the base prospectus dated 14 February 2014, 12 March 2014, 1 August 2014 and 7 November 2014 (together the " Base Prospectus ").

This announcement constitutes the Final Terms Confirmation Announcement in relation to the Final Terms for the purposes of Article 8(1) of directive 2003/71/EC, as amended, and must be read in conjunction with the Base Prospectus and the Final Terms. The Base Prospectus and the Final Terms are available for viewing at the registered office of the Issuer at Aleksis Kiven Katu 9, 00020 Nordea, Helsinki, Finland. The Base Prospectus is also available via the Issuer's website at www.nordea.com under Investor Relations:

http://www.nordea.com/Investor+Relations/Debt...25312.html

The Offer Period relating to the Notes expired at 16.00 CET on 12 December 2014, and accordingly Notes can no longer be subscribed pursuant to the offer. The Issuer confirms the following in connection with the offer and issue of the Notes:

Aggregate Nominal Amount:  
(a)      Series: DKK 48,690,000
(b)      Tranche: DKK 48,690,000
Issue Price: 106.00 per cent of the Aggregate Nominal Amount.
Replacement Factor: 28.00 per cent.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 0

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 206

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Air Sealing First: Boosting Home Comfort & Efficiency

Updated Category News Views 0

Everyone wants a cozy, energy-efficient home, right? Well, the first step to achieving that might just surprise you. Forget about shoving more insulation into the walls for a second; air sealing should be your starting line. That's the drum Insulation Expert Mike Mancuso is beating, and he's got a point worth considering before you touch another insulation panel. Cracking...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 64

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading
RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 50

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 208

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 79

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading
DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 287

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading
LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

Updated Category News Views 7

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 124

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading

Top 5 Most Recently Viewed Articles

Red Cat Holdings Faces Class Action Lawsuit from Investors

Updated Category News Views 209

Overview of the Class Action Against Red Cat Holdings Pomerantz LLP has announced that a class action lawsuit has been initiated against Red Cat Holdings, Inc. (RCAT) and certain officers due to allegations of misconduct. The legal action is filed in the United States District Court for the District of New Jersey. This lawsuit represents a class of individuals or entities...

Continue Reading
IPVanish: The Ultimate Solution for Cloud Storage Security

Updated Category News Views 129

IPVanish: Leading the Charge in Cloud Security As more individuals and businesses migrate to the cloud, the urgency for secure storage solutions has skyrocketed. IPVanish has stepped up to become a standout player in this landscape, recognized for its outstanding cloud access tools and strong privacy measures. Transformation into a Comprehensive Security Platform...

Continue Reading
Runway Growth Capital Bolsters Leadership with Rovner

Updated Category News Views 11

A New Era for Runway Growth Capital Alright folks, here's the scoop for anyone tracking the moves in the growth lending space: Michael Rovner, with his hefty 30-year career in the financial sector, is now taking on the role of Co-Chief Executive Officer and Co-Chief Investment Officer at Runway Growth Capital. This guy's a veteran, no doubt, having navigated the overlaps...

Continue Reading
Investors Anticipate Earnings from Booz Allen Hamilton Soon

Updated Category News Views 134

Market Expectations for Booz Allen Hamilton's Earnings Booz Allen Hamilton (NYSE: BAH) is set to unveil its quarterly earnings soon, and it's important for investors to be well-prepared. Analysts anticipate an earnings per share (EPS) of $1.51, a key figure to watch as it could impact stock sentiment significantly. Performance Insights and Analyst Predictions The hope...

Continue Reading
USD/JPY Holds Steady Amid Economic Shifts and Data Releases

Updated Category News Views 124

USD/JPY Stabilizes After Inflation Adjustments The USD/JPY currency pair has recently stabilized after a brief drop below the key level of 141.77. This dip happened just before the US Consumer Price Index (CPI) was announced, revealing an inflation rate of 2.5%. Following this data release, the currency pair started to rebound, thanks in part to a slight increase in US...

Continue Reading